XNCR's Upcoming Readouts (H2 '22)
Our biotwitter investor community generally does not see the upcoming readouts XNCR as big movers.
See our poll results:
Do you think the $XNCR vudalimab (anit-PD-1 & anti-CTLA-4) Ph2 mCRPC or the Ph1 NHL Plamotamab (anti-CD20xCD3) in Q4 will be big mover events for this stock?
#XNCR
#vudalimab
#Plamotamab
9 Views